ARAMIS Final Analysis: OS With Darolutamide Plus ADT vs Placebo Plus ADT for Nonmetastatic Castration-Resistant Prostate Cancer

May 29-31, 2020; Online at meetings.asco.org/am
Darolutamide plus ADT led to 31% risk reduction of death vs placebo plus ADT and no new safety concerns upon longer follow-up.
Format: Microsoft PowerPoint (.ppt)
File Size: 237 KB
Released: June 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Bayer HealthCare Pharmaceuticals Inc.
Bristol-Myers Squibb
Exelixis
Pfizer, Inc. and EMD Serono

Related Content

On-demand webcast of a live webinar on the urologist’s role in testing and using PARP inhibitors for prostate cancer, from Clinical Care Options (CCO)

person default Stephen Freedland, MD Rana R. McKay, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: November 30, 2022 Expired: November 29, 2023

On-demand webcast: Brenda Martone, MSN, ANP-BC, AOCNP, on best nursing practices for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Brenda Martone, MSN, ANP-BC, AOCNP Registered Nurses: 0.75 Nursing contact hours Released: November 3, 2022 Expired: November 2, 2023

Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)

person default Kathleen Burns, MSN, AGACNP-BC, OCN
Program Director
person default Brenda Martone, MSN, ANP-BC, AOCNP
Program Director
Released: October 19, 2022

Slides for urologists on single-agent and combination PARP inhibitor therapy for metastatic prostate cancer, from Clinical Care Options (CCO)

Rana R. McKay, MD Released: October 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings